Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | MTOR | P42345 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | BLM | P54132 | 3/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 6/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.54 |
| ▸ | HRH1 | P35367 | 6/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11338768 | 1.00 | SIGMAR1 (0.58) | SIGMAR1SCN5ACYP3A4CYP2D6MAPK1 | |
| Hydrochloric Acid SCHEMBL8627527 | 0.98 | MEN1 (0.58) | SIGMAR1SCN5ACYP3A4CYP2D6MAPK1 | |
| SCHEMBL10361883 | 0.94 | SCN5A (0.60) | SIGMAR1SCN5ACYP3A4CYP2D6MAPK1 | |
| SCHEMBL10556025 | 0.91 | SCN5A (0.58) | SIGMAR1SCN5ACYP3A4CYP2D6MAPK1 | |
| SCHEMBL7296899 | 0.90 | SIGMAR1 (0.61) | SIGMAR1SCN5ACYP3A4CYP2D6MAPK1 | |
| Hydrochloric Acid SCHEMBL10556477 | 0.89 | MEN1 (0.58) | SIGMAR1SCN5ACYP3A4CYP2D6MAPK1 | |
| SCHEMBL9119734 | 0.86 | SIGMAR1 (0.60) | SIGMAR1DRD3DRD2LMNACYP1A2 | |
| SCHEMBL8447051 | 0.85 | SIGMAR1 (0.62) | SIGMAR1MEN1KMT2ASLC6A4CHRM3 | |
| SCHEMBL10361920 | 0.84 | CCR1 (0.53) | SIGMAR1CYP2D6LMNACYP1A2SLC6A2 | |
| Hydrochloric Acid SCHEMBL7292331 | 0.84 | SIGMAR1 (0.60) | SIGMAR1MEN1KMT2ACHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-1120410-B1 | Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors | BIOVITRUM AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| EP-0673368-B1 | NOVEL NICOTINIC ACID ESTERS | BIOVITRUM AB (SE) | 2001-11-28 | — | — | EP | disclosed |
| EP-1120410-A1 | Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors | Pharmacia AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| EP-1059922-A2 | GLYCINE TRANSPORT INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-20 | — | — | EP | disclosed |
| EP-0637242-B1 | AGENTS FOR TREATING SUBSTANCE ABUSE DISORDERS | PHARMACIA & UPJOHN AB (SE) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999044596-A2 | GLYCINE TRANSPORT INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-10 | — | — | WO | disclosed |
| US-4492698-A | ANTIAGGRESSIVE, ANALGESIC, ANTIDEPRESSANT | AB FERROSAN (SE) | 1985-01-08 | — | — | US | disclosed |
| EP-0042366-B1 | DIPHENYLBUTYL-1-ACYLPIPERAZINES | AB Ferrosan (SE) | 1984-11-07 | — | — | EP | disclosed |
| US-4447433-A | ANALGESIC, ANTIARRHYTHMIA AGENTS | AB FERROSAN (SE) | 1984-05-08 | — | — | US | disclosed |
| US-4388237-A | NEUROLEPTIC, SEDATIVE, HYPNOTIC, ANALGESIC, ANTIDEPRESSANT | BASF AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| EP-0080992-A2 | 1-Piperazinocarboxylates, process for their preparation and pharmaceutical compositions containing them | AB Ferrosan (SE) | 1983-06-08 | — | — | EP | disclosed |
| US-4385057-A | TREATING MENTAL AND PSYCHOSOMATIC DISORDERS | AB FERROSAN (SE) | 1983-05-24 | — | — | US | disclosed |
| US-4336192-A | ANALGESICS, SEDATIVES, ANTICHOLINERGIC AGENTS, ANTIEMETICS | BASF AKTIENGESELLSCHAFT (DE) | 1982-06-22 | — | — | US | disclosed |
| US-4308387-A | ANTIPSYCHOTIC, ANTIDEPRESSANT, ANALGESIC | AB FERROSAN (SE) | 1981-12-29 | — | — | US | disclosed |
| EP-0042366-A1 | Diphenylbutyl-1-acylpiperazines | AB Ferrosan (SE) | 1981-12-23 | — | — | EP | disclosed |
| US-4243805-A | 3 Fluoro-10-piperazino-8-substituted 10,11-dihydrodibenzo-(bf) thiepins and method for the preparation thereof | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | SIGMAR1 598/4885SCN5A 1404/4885CYP3A4 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.